C030017K20Rik Inhibitors
C030017K20Rik, a product of the RIKEN cDNA C030017K20 gene, plays a pivotal role in cellular processes, potentially involving gene expression regulation. While the identification of direct inhibitors for C030017K20Rik remains elusive, a theoretical exploration into potential inhibitors targeting key signaling pathways provides valuable insights into prospective avenues for future investigations. The intricate interplay of C030017K20Rik with pathways such as PI3K-AKT, MAPK/ERK, TGF-β, and JNK emphasizes the complexity of its regulatory mechanisms. Staurosporine, an unspecific kinase inhibitor, exemplifies the diverse range of potential inhibitors that could impact C030017K20Rik by modulating essential signaling pathways. SB203580, as a p38 MAP kinase inhibitor, has the potential to indirectly affect C030017K20Rik by disrupting the p38 MAP kinase activity, a key regulator implicated in gene expression dynamics. Wortmannin and LY294002, both acting as inhibitors of PI3K, may intricately influence cellular responses associated with C030017K20Rik by disrupting the PI3K-AKT pathway. PD98059, a MEK inhibitor, is envisaged to impact C030017K20Rik by altering the MAPK/ERK pathway. SP600125, a JNK inhibitor, could influence the protein by suppressing c-Jun N-terminal kinase activity, altering cellular stress responses linked to C030017K20Rik.
U0126, SB431542, and SB202190, acting on the MAPK and TGF-β pathways, offer potential avenues for indirectly influencing C030017K20Rik by disrupting key signaling cascades. AZD5363, as an AKT kinase inhibitor, is anticipated to modulate cellular processes linked to C030017K20Rik by altering the PI3K-AKT pathway. VX-745, a JAK2 inhibitor, may impact C030017K20Rik by influencing downstream STAT signaling. Rapamycin, as an mTOR inhibitor, has the potential to alter cellular processes associated with C030017K20Rik, affecting the landscape of gene expression. In conclusion, while direct inhibitors for C030017K20Rik are yet to be identified, the exploration of potential inhibitors targeting pivotal signaling pathways provides a foundation for future investigations. The intricate interplay of C030017K20Rik with pathways such as PI3K-AKT, MAPK/ERK, TGF-β, and JNK necessitates further scrutiny to unravel the specific mechanisms governing its function and potential avenues for modulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, with CAS Number 62996-74-1, is a broad-spectrum kinase inhibitor targeting various protein kinases. Its influence on cellular processes may disrupt signaling pathways crucial for C030017K20Rik, potentially impacting its regulatory mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, identified by CAS Number 152121-47-6, is a p38 MAP kinase inhibitor. Its impact on the MAPK pathway, particularly p38 MAP kinase, may indirectly affect C030017K20Rik by altering the dynamics of cellular responses associated with this enigmatic protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, recognized by CAS Number 19545-26-7, is a phosphoinositide 3-kinase (PI3K) inhibitor. Its modulation of the PI3K-AKT pathway is envisaged to influence C030017K20Rik indirectly, perturbing the signaling cascades converging upon its regulatory domains and potentially impacting its functionality. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, with CAS Number 167869-21-8, serves as a MEK inhibitor, disrupting the MAPK/ERK pathway. The hypothetical impact of PD98059 on C030017K20Rik involves the inhibition of MEK1, thereby altering the MAPK signaling cascade and influencing the protein's regulatory mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, functioning as a PI3K inhibitor and identified by CAS Number 154447-36-6, is anticipated to intricately influence cellular responses linked to C030017K20Rik by modulating the PI3K-AKT pathway, potentially altering the dynamics of gene expression and cellular processes associated with this protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, acting as a JNK inhibitor and represented by CAS Number 129-56-6, may indirectly influence C030017K20Rik by suppressing c-Jun N-terminal kinase activity. This suppression could impact gene expression dynamics associated with C030017K20Rik by altering cellular stress responses. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, identified by CAS Number 301836-41-9, is a selective inhibitor of the TGF-β type I receptor ALK5. Its modulation of the TGF-β pathway may indirectly impact C030017K20Rik by altering the signaling cascade related to this pathway, potentially influencing the protein's regulatory mechanisms. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190, acting as a p38 MAP kinase inhibitor with CAS Number 152121-30-7, may indirectly influence C030017K20Rik by disrupting p38 MAP kinase activity. The disruption of this kinase, a key regulator implicated in gene expression dynamics, could impact the regulatory mechanisms of C030017K20Rik. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, with CAS Number 1143532-39-1, is an AKT kinase inhibitor. Its modulation of the PI3K-AKT pathway is anticipated to intricately influence cellular processes linked to C030017K20Rik, potentially altering the dynamics of gene expression and regulatory mechanisms associated with this protein. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745, denoted by CAS Number 209410-46-8, is an envisioned JAK2 inhibitor that targets the JAK-STAT pathway. The speculative influence of VX-745 on C030017K20Rik centers around its capacity to impact downstream STAT signaling, potentially altering the cellular responses linked to the protein's regulatory mechanisms. | ||||||